Biography

Prof Murray Brunt is Chief investigator on the FAST-Forward £3.6m NIHR-HTA funded trial and two others and active on 8 national/international breast cancer trial management groups. For the majority of trials in which he has been involved, Prof Brunt has been the principal investigator for North Staffordshire and  involved in all local aspects from the initiation, set up, recruitment through to follow up until trial closure.

Prof Brunt initiated the first weekly clinical trial follow up clinic in the Guy Hilton Research Centre, which has been running since 2007.  He been a major collaborator on a total of over 60 national or international studies and has just been appointed the first NIHR-Cancer Research lead for the West Midlands in the new national research set-up.

Research and scholarship

ISTM Research theme: Therapeutics

Prof Brunt’s research is in breast cancer, haematological malignancies (predominantly lymphomas), and skin cancer. It is conducted primarily through breast cancer clinical trials, on three levels:

  • trial development, management, and  publication of results.
  • a principal investigator and recruiter to trials
  • the practical application of clinical trials and patient interaction.

The areas of breast cancer trials in which Prof Brunt is involved directly relate to his practice as a clinical oncologist:

  • radiotherapy, 
  • chemotherapy, 
  • hormone therapy,
  • targeted biological therapy

 

Further information

Professional Memberships:

  • Medical Defence Union
  • Royal College of Radiologists
  • Royal College of Physicians, London
  • British Oncology Association
  • Radiotherapists Visiting Society
  • Hospital Consultant & Specialists Association
  • North Staffordshire Medical Institute

Committee Memberships:

  • National deputy lead for the Breast Site Orientated electronic Network (SOeN): 2006-present.
  • Member of National Collaborating Centre for Cancer (NCCC) advanced breast cancer guideline development group: 2006-9 (the lifetime of the project).
  • Member of West Midlands Cancer Intelligence Unit steering committee: 2005-present.
  • Member of Regional peer review team from 1997, clinical team leader from 2005-present.
  • Chair of R & D steering committee: 2007 to present.
  • Deputy Lead of NCRN R & D for North West Midlands Cancer Network 2004-6 (until networks amalgamated).

Selected Publications

  • Yarnold JR, Brunt AM, Chatterjee S, Somaiah N, Kirby AM. 2022. From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy. Clin Oncol (R Coll Radiol), 332-339, vol. 34(5). link> doi>
  • Ingram J, Beasant L, Benson J, Brunt AM, Maxwell A, Harvey JR, Greenwood R, Roberts N, Williams N, Johnson D, Winters Z. 2022. The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trial. Pilot Feasibility Stud, 46, vol. 8(1). link> doi>
  • Bundred N, Porta N, Brunt AM, Cramer A, Hanby A, Shaaban AM, Rakha EA, Armstrong A, Cutress RI, Dodwell D, Emson MA, Evans A, Hartup SM, Horgan K, Miller SE, McIntosh SA, Morden JP, Naik J, Narayanan S, Ooi J, Skene AI, Cameron DA, Bliss JM. 2022. Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clin Cancer Res, 1323-1334, vol. 28(7). link> doi>
  • Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, Offersen BV, Aznar MC, Belka C, Brunt AM, Dicuonzo S, Franco P, Krause M, MacKenzie M, Marinko T, Marrazzo L, Ratosa I, Scholten A, Senkus E, Stobart H, Poortmans P, Coles CE. 2022. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. The Lancet Oncology, e21-e31, vol. 23(1). link> doi> link> full text>
  • Coles C, Haviland JS, Kirby AM, Bhattacharya I, Brunt AM, Chan C, Donovan EM, Eaton DJ, Griffin CL, Hopwood P, Jefford ML, Lightowlers S, Rajapakse C, Sawyer E, Stones L, Syndikus I, Titley JC, Tsang Y, Twyman NI, Bliss JM, Yarnold JR. 2021. IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. RADIOTHERAPY AND ONCOLOGY (pp. S197-S199, vol. 161). link> doi> full text>

Full Publications Listshow

Journal Articles

  • Yarnold JR, Brunt AM, Chatterjee S, Somaiah N, Kirby AM. 2022. From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy. Clin Oncol (R Coll Radiol), 332-339, vol. 34(5). link> doi>
  • Ingram J, Beasant L, Benson J, Brunt AM, Maxwell A, Harvey JR, Greenwood R, Roberts N, Williams N, Johnson D, Winters Z. 2022. The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trial. Pilot Feasibility Stud, 46, vol. 8(1). link> doi>
  • Bundred N, Porta N, Brunt AM, Cramer A, Hanby A, Shaaban AM, Rakha EA, Armstrong A, Cutress RI, Dodwell D, Emson MA, Evans A, Hartup SM, Horgan K, Miller SE, McIntosh SA, Morden JP, Naik J, Narayanan S, Ooi J, Skene AI, Cameron DA, Bliss JM. 2022. Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clin Cancer Res, 1323-1334, vol. 28(7). link> doi>
  • Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, Offersen BV, Aznar MC, Belka C, Brunt AM, Dicuonzo S, Franco P, Krause M, MacKenzie M, Marinko T, Marrazzo L, Ratosa I, Scholten A, Senkus E, Stobart H, Poortmans P, Coles CE. 2022. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. The Lancet Oncology, e21-e31, vol. 23(1). link> doi> link> full text>
  • Brunt AM, Haviland JS, Kirby AM, Somaiah N, Wheatley DA, Bliss JM, Yarnold JR. 2021. Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical Oncology, 430-439, vol. 33(7). link> doi> link> full text>
  • Lewis P, Brunt AM, Coles C, Griffin S, Locke I, Roques T, Breast Radiotherapy Consensus Working Group. 2021. Editorial: Moving Forward Fast with FAST-Forward. Clinical Oncology, 427-429, vol. 33(7). link> doi> link>
  • Obeng-Gyasi S, Coles CE, Jones J, Sacks R, Lightowlers S, Bliss JM, Brunt AM, Haviland JS, Kirby AM, Kalinsky K. 2021. When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology educational book, 1-11, vol. 41. link> doi> link>
  • Hoskin P, Popova B, Schofield O, Brammer C, Robinson M, Brunt AM, Madhavan K, Illidge T, Gallop-Evans E, Syndikus I, Clifton-Hadley L, Kirkwood AA. 2021. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, 332-340, vol. 21(3). link> doi> link> full text>
  • Brunt AM, Haviland JS, Wheatley DA, Yarnold JR. 2020. Breast cancer radiation therapy - Authors' reply. Lancet, 1559-1560, vol. 396(10262). link> doi> full text>
  • Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, Barrett-Lee P, Bliss P, Bloomfield D, Bowen J, Donovan E, Goodman A, Harnett A, Hogg M, Kumar S, Passant H, Quigley M, Sherwin L, Stewart A, Syndikus I, Tremlett J, Tsang Y, Venables K, Wheatley D, Bliss JM, Yarnold JR. 2020. Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. J Clin Oncol, 3261-3272, vol. 38(28). link> doi> full text>
  • Manoj Gowda S, Kabeer KK, Jafferbhoy S, Marla S, Soumian S, Misra V, Narayanan S, Brunt AM. 2020. Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian J Surg, 1-8. link> doi> full text>
  • Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR, FAST-Forward Trial Management Group. 2020. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet, 1613-1626, vol. 395(10237). link> doi> full text>
  • Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, Hanna G, Jagsi R, Kaidar Person O, Kirby A, Mjaaland I, Meattini I, Luis AM, Marta GN, Offersen B, Poortmans P, Rivera S. 2020. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin Oncol (R Coll Radiol), 279-281, vol. 32(5). link> doi> full text>
  • King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH, BIG 3-07/TROG 07.01 trial investigators. 2020. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol, 685-698, vol. 21(5). link> doi>
  • Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero J-M, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker S-J, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. 2020. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol, 423-433, vol. 38(5). link> doi> full text>
  • Fernando IN, Bowden SJ, Herring K, Brookes CL, Ahmed I, Marshall A, Grieve R, Churn M, Spooner D, Latief TN, Agrawal RK, Brunt AM, Stevens A, Goodman A, Canney P, Bishop J, Ritchie D, Dunn J, Poole CJ, Rea DW, SECRAB Investigators. 2019. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology. link> doi> full text>
  • Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, Schenker M, Sohn J, Lee KS, Shepherd CJ, Oelmann E, Sarker S-J, Prendergast A, Marosics P, Moosa A, Lawrence C, Coetzee C, Mousa K, Cortés J. 2019. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 1556, vol. 5(11). doi> link> full text>
  • Hoskin P, Kirkwood A, Popova B, Schofield O, Brammer C, Robinson M, Brunt M, Krishnaswamy M, Illidge T, Gallop-Evans E, Syndikus I, Clifton-Hadley L. 2019. LONG TERM FOLLOW-UP OF FoRT: A PHASE 3 MULTI-CENTER PROSPECTIVE RANDOMIZED TRIAL OF RADIATION THERAPY FOR FOLLICULAR AND MARGINAL ZONE LYMPHOMA. Hematological Oncology, 219-220, vol. 37. doi>
  • Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K, Peoples GE. 2019. Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clin Cancer Res, 4248-4254, vol. 25(14). link> doi>
  • Cumins SM and Brunt AM. 2000. Does Acupuncture Influence the Vasomotor Symptoms Experienced by Breast Cancer Patients Taking Tamoxifen?. Acupuncture in Medicine, 28, vol. 18(1). doi>
  • Brunt AM, Haviland J, Sydenham M, Algurafi H, Alhasso A, Bliss P, Bloomfield D, Emson M, Goodman A, Harnett A, Passant H, Tsang YM, Wheatley D, Bliss J, Yarnold J. 2018. FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology*Biology*Physics, 1603-1604, vol. 102(5). doi> link>
  • Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS, MRC SUPREMO trial UK investigators. 2018. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol, 1516-1529, vol. 19(11). link> doi> full text>
  • Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR, AVAST-M Investigators, Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan K, Coltart R, Gee B, Gore M, Farrugia D, Martin-Clavijo A, Marsden J, Price C, Farrugia D, Nathan K, Coltart R, Nathan K, Coltart R. 2018. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 1843-1852, vol. 29(8). link> doi> link> full text>
  • Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR, Beswick A, Greenwood R, Ingram JC, Saunders C, Vaidya JS, Esserman L, Jatoi I, Brunt AM. 2018. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open, 162-174, vol. 2(4). link> doi> link> full text>
  • Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM, IMPORT Trialists. 2017. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 1048-1060, vol. 390(10099). link> doi> full text>
  • Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM, TACT2 Investigators. 2017. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol, 929-945, vol. 18(7). link> doi> full text>
  • Pai K, Gilani S, Brunt M. 2017. Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting. Clinical Oncology, e102-e103, vol. 29(6). doi> link> full text>
  • Price L and Brunt AM. 2018. Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?. Eur J Hosp Pharm, 331-333, vol. 25(6). link> doi> full text>
  • Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, Bliss JM, Grp F-FTM. 2016. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. RADIOTHERAPY AND ONCOLOGY, 114-118, vol. 120(1). link> doi> link> full text>
  • Coles C, Agrawal R, Ah-See ML, Algurafi H, Alhasso A, Brunt AM, Chan C, Griffin C, Harnett A, Hopwood P, Kirby A, Sawyer E, Syndikus I, Titley J, Tsang Y, Wheatley D, Wilcox M, Yarnold J, Bliss JM, TMG I. 2016. Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). EUROPEAN JOURNAL OF CANCER, S4, vol. 57. link> doi> link>
  • Brunt AM, Lupton S, Thorley K, Pearce L, Handley J. 2016. Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer. Rep Pract Oncol Radiother, 219-224, vol. 21(3). link> doi>
  • Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM, Breast MIAMIMI. 2016. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. BREAST, 149-150, vol. 26. link> doi>
  • Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne C-H, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, Herceptin Adjuvant (HERA) Trial Study Team. 2013. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 1021-1028, vol. 382(9897). link> doi>
  • Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im Y-H, Braybrooke JP, Brunt AM, Cheung K-L, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin H-J, Folkerd E, Dowsett M, Bliss JM, Investigators S. 2013. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. LANCET ONCOLOGY, 989-998, vol. 14(10). link> doi>
  • Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. 2013. Breast Radiotherapy: Less is More?. CLINICAL ONCOLOGY, 127-134, vol. 25(2). link> doi>
  • Earl HM, Hiller L, Dunn JA, Vallier A-L, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RCF, Twelves CJ, Cameron D, Bartlett JMS, Pharoah P, Provenzano E, Caldas C, Poole CJ. 2012. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 1257-1267, vol. 107(8). link> doi> full text>
  • Chan KWK, Kalra S, Kirby RM, Brunt AM, Hawkins CP. 2012. Epileptic seizure abolition with aromatase inhibition. Journal of Neurology, Neurosurgery & Psychiatry, 1249-1250, vol. 83(12). doi>
  • Fernando I, Bowden SJ, Brookes CL, Grieve R, Spooner D, Agrawal RK, Brunt AM, Churn M, Rea DW, Canney P. 2011. Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee. European Journal of Cancer, 2, vol. 47. doi>
  • Yarnold JR, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, Bloomfield D, Bowen J, Brunt AM, Donovan E, Emson M, Goodman A, Harnett A, Haviland JS, Kaggwa R, Morden JP, Robinson A, Simmons S, Stewart A, Sydenham MA, Syndikus I, Tremlett J, Tsang Y, Wheatley D, Venables K, Grp FASTT. 2011. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). RADIOTHERAPY AND ONCOLOGY, 93-100, vol. 100(1). link> doi>
  • Stringer NJ, Fitzpatrick RW, Brunt AM. 2011. Economic evaluation of a standard dosage system for an outpatient breast cancer chemotherapy regimen. International Journal of Pharmacy Practice, 185-189, vol. 9(3). doi>
  • Hardwicke J, Brunt AM, Rylands G, Rayatt S. 2011. Ten-year Audit of Melanoma in a Central England Population*. Acta Dermato Venereologica, 440-443, vol. 91(4). doi>
  • Samee A, Kirby RM, Brunt AM. 2010. Passage of intestinal (small bowel) cast - an unusual complication of neutropenic sepsis. Case Reports, bcr0420102924, vol. 2010(jul22 1). doi>
  • Murray N, Brunt M, Macbeth F, Winstanley J, Guideline Development Group. 2009. Advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence Guideline 2009 - a solid basis for good clinical practice. Clin Oncol (R Coll Radiol), 368-370, vol. 21(5). link> doi>
  • Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A, Grieve RJ, Agrawal RK, Fernando IN, Brunt AM, McAdam K, O'Reilly S, Rea DW, Spooner D, Poole CJ. 2008. NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life. British Journal of Cancer, 1226-1231, vol. 99(8). doi>
  • 2008. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet, 1098-1107, vol. 371(9618). doi>
  • 2007. Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. JNCI Journal of the National Cancer Institute, 516-525, vol. 99(7). doi>
  • 2007. Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. JNCI Journal of the National Cancer Institute, 506-515, vol. 99(7). doi>
  • Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RCF, Twelves CJ. 2006. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. New England Journal of Medicine, 1851-1862, vol. 355(18). doi>
  • Featherstone CJ, Harnett AN, Brunt AM, Johnson L. 2002. Methods of ovarian suppression used in the UK. The Breast, 23-29, vol. 11(1). doi>
  • Hartley A, Spooner D, Brunt AM. 2001. Management of Malignant Phaeochromocytoma: A Retrospective Review of the use of MIBG and Chemotherapy in the West Midlands. Clinical Oncology, 361-366, vol. 13(5). doi>
  • Featherstone C, Harnett AN, Brunt AM. 1999. Ultrasound Localization of the Ovaries for Radiation-Induced Ovarian Ablation. Clinical Oncology, 393-397, vol. 11(6). doi>
  • Sulé-Suso J, Scoble JE, Adab FA, Jones PW, Brunt AM. 1997. Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. 5 years follow-up. European Journal of Cancer, S106, vol. 33. doi>
  • YARNOLD JR, BLISS JM, BRUNT M, EARL H, KAYE S, MASON M, MOSSMAN J, PERREN T, RICHARDS M. 1994. MANAGEMENT OF BREAST - REFER WOMEN TO MULTIDISCIPLINARY BREAST CLINICS. BRITISH MEDICAL JOURNAL, 714-715, vol. 308(6930). link> doi>
  • Brunt AM and the ABC Trial Steering Committee. 1994. The UKCCCR adjuvant breast cancer (ABC) trial. Clinical Oncology, 209-210, vol. 6(4). doi>
  • Brunt AM, Sule-Suso J, Scoble JE. 1992. Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. Clinical Oncology, 340, vol. 4(5).
  • Sule-Suso J and Brunt AM. 1992. Oat cell carcinoma of the prostate. British Journal of Radiology, 726-728, vol. 65.
  • Brunt AM and Scoble JE. 1992. Para-aortic nodal irradiation for early stage testicular seminoma. Clinical Oncology, 165-170, vol. 4(3). doi>
  • Sule-Suso J, Brunt AM, Lindup R, Scoble JE. 1991. Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. Clinical Oncology, 209-213, vol. 3. doi>
  • RETSAS S, BAFALOUKOS D, BRUNT A. 1991. α-interferons: Impact on survival of patients with renal cell carcinoma. Clinical Oncology, 273-277, vol. 3. doi>
  • Brunt AM and Phillips RH. 1990. Strontium-90 for conjunctival AIDS-related Kaposi's sarcoma: The first case report. Clinical Oncology, 118-119, vol. 2(2). doi>
  • Barr LC, Brunt AM, Goodman AG, Phillips RH, Ellis H. 1989. Uncontrolled local recurrence after treatment of breast cancer with breast conservation. Cancer, 1203-1207, vol. 64(6). doi>
  • Brunt AM, Goodman AG, Phillips RH, Youle MS, Gazzard BG. 1989. The safety of intravenous chemotherapy and zidovudine when treating epidemic Kaposiʼs sarcoma. AIDS, 457-460, vol. 3(7). doi>

Other

  • Coles C, Haviland JS, Kirby AM, Bhattacharya I, Brunt AM, Chan C, Donovan EM, Eaton DJ, Griffin CL, Hopwood P, Jefford ML, Lightowlers S, Rajapakse C, Sawyer E, Stones L, Syndikus I, Titley JC, Tsang Y, Twyman NI, Bliss JM, Yarnold JR. 2021. IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. RADIOTHERAPY AND ONCOLOGY (pp. S197-S199, vol. 161). link> doi> full text>
  • Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield D, Chan C, Churn M, Cleator S, Coles CE, Emson M, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan C, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Wilcox M, Bliss JM, Yarnold JR. 2020. FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. RADIOTHERAPY AND ONCOLOGY (pp. S346-S347, vol. 152). link> doi> full text>
  • Winters ZE, Jones L, Schmidt P, Brunt M, Maxwell A, Ingram J, Greenwood R, Kandiyali R, Roberts N, Brew-Graves C, Potyka I, Williams N. 2020. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654). BREAST CANCER RESEARCH AND TREATMENT (pp. 564-565, vol. 180). BRITISH SOCIETY OF BREAST RADIOLOGY. link> link>
  • Winters Z, Roberts N, Brunt M, Greenwood R, Maxwell A, Potyka I, Ingram J, Kandiyali R, McCartan N, Schmid P, Williams N. 2019. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK. ANNALS OF SURGICAL ONCOLOGY (pp. 58-60, vol. 26). link>
  • Coles CE, Griffin CL, Kirby AM, Haviland JS, Titley JC, Benstead K, Brunt AM, Chan C, Ciurlionis L, Din OS, Donovan EM, Eaton DJ, Harnett AN, Hopwood P, Jefford ML, Jenkins PJ, Lee CE, McCormack M, Sherwin L, Syndikus I, Tsang Y, Twyman NI, Ventikaraman R, Wickers S, Wilcox MH, Bliss JM, Yarnold JR. 2019. Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). CANCER RESEARCH (vol. 79). link> doi>
  • Brunt AM, Haviland J, Sydenham M, Alhasso A, Bloomfield D, Chan C, Churn M, Cleator S, Coles C, Emson M, Goodman A, Griffin C, Harnett A, Hopwood P, Kirby A, Kirwan C, Morris C, Sawyer E, Somaiah N, Syndikus I, Wilcox M, Rada Z, Wheatley D, Bliss J, Yarnold J. 2018. FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. BRITISH JOURNAL OF CANCER (p. 41, vol. 119). link>
  • Schmid P, Abraham J, Chan S, Wheatley D, Brunt M, Nemsadze G, Baird R, Park YH, Hall P, Perren T, Stein RC, Laszlo M, Ferrero J-M, Phillips M, Conibear J, Sarker S-J, Prendergast A, Cartwrightx H, Mousa K, Turner NC. 2018. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. JOURNAL OF CLINICAL ONCOLOGY (vol. 36). link> doi>
  • Yoganayagam N, Tripathy A, Exton S, Rawet T, Wu KS, Brunt AM, Gahir D, Jegannathen A. 2018. Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. EUROPEAN JOURNAL OF CANCER (p. S119, vol. 92). link>
  • Brunt AM, Haviland J, Sydenham M, Al-hasso A, Bloomfield D, Chan C, Churn M, Cleator S, Coles C, Emson M, Goodman A, Griffin C, Harnett A, Hopwood P, Kirby A, Kirwan C, Morris C, Sawyer E, Somaiah N, Syndikus I, Wilcox M, Zotova R, Wheatley D, Bliss J, Yarnold J. 2018. FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. RADIOTHERAPY AND ONCOLOGY (pp. S311-S312, vol. 127). link> doi>
  • Fullagar A, Sodhi L, Pillai S, Brunt M. 2018. Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification. BRITISH JOURNAL OF HAEMATOLOGY (pp. 166-167, vol. 181). link>
  • Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Cabrero IR, Perello A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Mahr K, Schenker M, Sohn JH, Lee KS, Sarker S-J, Coetzee C, Mousa K, Castan JC. 2018. MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. CANCER RESEARCH (vol. 78). link> doi>
  • Megias D, Sydenham M, Wheatley D, Maclennan M, Spezi E, Brunt AM. 2017. Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy. RADIOTHERAPY AND ONCOLOGY (pp. S136-S137, vol. 123). link> doi>
  • Coles C, Griffin C, Kirby A, Agrawal R, Alhasso A, Bhattacharya I, Brunt AM, Ciurlionis L, Chan H, Donovan E, Emson M, Harnett A, Haviland J, Hopwood P, Jefford M, Kaggwa R, Sawyer E, Sybdikus I, Tsang Y, Wheatley D, Wilcox M, Yarnold J, Bliss J. 2017. Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. RADIOTHERAPY AND ONCOLOGY (pp. S162-S163, vol. 123). link> doi>
  • Brunt AM, Sydenham M, Bliss J, Coles C, Gothard L, Harnett A, Haviland J, Syndikus I, Wheatley D, Yarnold J. 2009. A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015). EJC SUPPLEMENTS (p. 2, vol. 7). link> doi>
  • Bloomfield D, Sydenham M, Le Vay J, Syndikus I, Hatton M, Bliss P, Dyson P, Kelly S, Agrawal R, Barrett-Lee P, Abson C, Owen JR, Kumar S, Brunt M, Whipp L, Illsley M, Bliss J, Yarnold J. 2004. Prospective randomised trial testing 5.7GY and 6.0GY fractions of whole breast radiotherapy in women with early breast cancer ('fast' trial). BRITISH JOURNAL OF CANCER (p. S80, vol. 91). link>
  • SuleSuso J, Scoble JE, Adab FA, Jones PW, Brunt AM. 1997. Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. 5 years follow-up. EUROPEAN JOURNAL OF CANCER (p. 468, vol. 33). link>

School of Medicine
David Weatherall building
University Road
Keele University
Staffordshire
ST5 5BG